Schizophrenia is a devastating chronic psychotic disorder characterized by positive,
negative, and cognitive symptoms. Although the positive symptoms are relatively well …

Schizophrenia is a chronic psychiatric disorder which substantially impairs patients' quality
of life. Despite the extensive research in this field, the pathophysiology and etiology of …

Group II metabotropic glutamate (mGlu) receptor agonists were efficacious in randomized
clinical research trials for schizophrenia and generalized anxiety disorder. The regional …

Striatal medium spiny neurons (MSNs) receive glutamatergic afferents from the cerebral
cortex and dopaminergic inputs from the substantia nigra (SN). Striatal dopamine loss …

The treatment of schizophrenia for the last half century has been with dopamine (DA) D 2
receptor blockers, implicating a hyperdopamine basis for psychosis. However, a 2007 report …

Rationale Current antipsychotics are ineffective at treating the negative and cognitive
symptoms of schizophrenia, so there is a substantial need to develop more effective …

Group II metabotropic glutamate receptor (mGluR2/3) agonists once showed promise as non-
dopaminergic antipsychotic drugs because of their efficacy in alleviating symptoms of …

A long-term search for the mechanism of action of antipsychotic drugs was motivated by a
search for the cause of schizophrenia. The research between 1963 and 1975 led to the …

Glutamate exerts its effects through binding and activation of two classes of specific
receptors: ionotropic (iGluRs) and metabotropic (mGluRs). Group I mGluR includes mGluR1 …

Rationale Activation of metabotropic glutamate (mGlu) 2/3 receptors may provide a novel
strategy for treating schizophrenia. This effect is thought to be mediated through dopamine …